Understanding cannabis use and its effects on depression and suicide risk in adolescents
Official title: Characterizing Proximal Risk for Depressive Symptoms and Suicidal Ideation With Acute Cannabis Use and Withdrawal Among Adolescents Using Ecological Momentary Assessment
Run by Massachusetts General Hospital · NCT06576076 · Data updated 2026-11-12
This study is trying to see how stopping cannabis use affects depression and suicidal thoughts in teens aged 12-18 who use cannabis daily.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 12 Years to 18 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | February 18, 2025 |
| Main results expected | April 30, 2029 |
| Study ends | April 30, 2029 |
| Registry record updated | March 3, 2026 |
| Trial ID | NCT06576076 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adolescents aged 12-18 who use cannabis daily and show current symptoms of depression.
✕Probably not a fit
Patients who do not use cannabis regularly or do not exhibit depressive symptoms may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore the relationships between cannabis use, withdrawal, depression, and suicidal ideation in adolescents aged 12-18 years. It will recruit 200 participants who use cannabis daily and exhibit symptoms of depression. The study involves a 10-week protocol, including a 2-week baseline phase with real-time monitoring of mood and substance use, followed by an 8-week randomization phase comparing cannabis abstinence with contingency management versus non-contingent monitoring. The goal is to develop effective interventions to reduce depression and suicide risk among adolescents.
Why it matters
Potential benefit: If successful, this study could lead to tailored interventions that significantly reduce depression and suicide risk in adolescents who use cannabis.
How similar studies have gone: Other studies have shown promising results in understanding the effects of substance use on mental health, but this specific approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ages 12-18; * Current daily or near daily cannabis use (i.e., use ≥ 4 days per week on average; Timeline Followback); * Score ≥ 5 on PHQ-9; * Access to an internet-capable smartphone (iOS or Android); * Provision of at least 1 collateral contact for risk monitoring; * Provision of informed assent (or consent if 18 years or older) and parent/guardian consent if \<age 18; * Greater than 50% response rate to EMA prompts during the first EMA phase; * No immediate plan to discontinue cannabis use in the next 3 months; * Positive toxicology result for cannabis on baseline urinalysis. Exclusion Criteria: * Any factor that impairs ability to comprehend and effectively participate, including acute intoxication at time of consent; * Cannabis use \>4 times/day on average (to maximize likelihood of capturing mood and SI during non-use times); * Inability to speak/write English fluently; * Gross cognitive impairment, for example due to florid psychosis, intellectual disability, developmental delay, or neurodegenerative disease; * Current epilepsy diagnosis; * Individuals who are under the legal protection of the government or state (wards of the state); * Response of "No" to the knowledge check question regarding EMA suicidality response time; * Inability to wear Fitbit device.
Where it's running
-
Massachusetts General Hopsital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Randi M Schuster, PhD — Massachusetts General Hospital
- Study coordinator: Randi M Schuster, PhD
- Email: rschuster@mgh.harvard.edu
- Phone: 617-643-6673
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of cannabis on brain function in depressed adolescents
This study is testing how using cannabis affects brain function in teenagers who are dealing with depression.
-
Teacher-led mental health care for adolescents
This study is testing a new way for trained teachers to provide mental health support to teenagers in rural schools to see if it helps them with emotional and behavioral challenges.
-
Evaluating the effects of PRISMA on mental health in pretrial detainees
This study is testing a new therapy program called PRISMA to see if it can help improve the mental health of people held in pretrial detention.
-
Using ketamine to help suicidal patients in the emergency department
This study is testing if a low dose of ketamine can safely help people in the emergency department who are feeling suicidal by reducing their symptoms and possibly shortening their hospital stay.
-
Exploring brain activity and emotional processing in healthy individuals and those with depression
This study is trying to see how brain activity related to emotions works differently in healthy people and those with depression, to help find better treatments for emotional challenges.
-
Psychotherapy to improve brain function and reduce suicidality in older adults
This study is testing a new therapy called Engage & Connect to see if it can help older adults with depression and suicidal thoughts by improving their brain function and encouraging social connections.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.